Tykerb 250 mg Alternative – Certus (Lapatinib) 250 mg Tablet | Beacon Pharmaceuticals
Certus 250 mg (Lapatinib) Tablet by Beacon Pharmaceuticals. Reference brand: Tykerb. HER2/EGFR inhibitor; used in selected HER2-positive breast cancer combinations. Prescription medicine. Brand comparison does not establish interchangeability.
Product Overview
Certus 250 mg Tablet is listed in the supplied Beacon Pharmaceuticals anti-cancer and hematology price list. The stated active ingredient is Lapatinib. Tykerb is a reference brand for the generic ingredient. This is a product-identification comparison, not a claim of verified bioequivalence or interchangeability.
Certus vs Tykerb – Reference Brand Comparison
Tykerb is a recognized reference brand associated with Lapatinib. Certus is listed under Beacon Pharmaceuticals. Their excipients, marketing authorizations, formulation details and regulatory evidence may differ. A clinician or pharmacist must confirm whether substitution is appropriate.
Composition and Active Ingredient
Brand: Certus. Active ingredient: Lapatinib. Strength: 250 mg. Dosage form: Tablet. Therapeutic class: HER2/EGFR inhibitor. Listed manufacturer: Beacon Pharmaceuticals Ltd., Bangladesh. Packaging details should be confirmed on the manufacturer’s current pack.
Therapeutic Uses and Indications
Lapatinib is used in selected HER2-positive breast cancer combinations. These are generic-level clinical contexts and do not independently confirm every indication for this particular branded presentation. Eligibility may depend on biomarkers, previous therapy and country-specific labeling.
Mechanism of Action – How Lapatinib Works
Lapatinib blocks HER2 and EGFR signaling. This mechanism alone does not establish suitability or effectiveness for an individual patient.
Dosage and Administration
The 250 mg shown is the strength of this tablet, not a recommended daily dose. Dose, timing, food instructions and treatment duration must be determined by the treating specialist using the current authorized prescribing information. Do not change dose or substitute brands or strengths without medical approval.
Contraindications
Contraindications depend on Lapatinib, formulation and individual medical conditions. Review the current official prescribing information, particularly hypersensitivity, pregnancy-related and organ-function restrictions.
Warnings and Precautions
Important safety considerations include diarrhea, liver injury and cardiac effects. The prescriber may require laboratory testing, cardiac or organ-function assessment, and ongoing monitoring.
Possible Side Effects
Potential adverse effects and serious reactions include diarrhea, liver injury and cardiac effects. Other reactions can occur. Consult the product leaflet for the full adverse-effect profile and seek medical care for severe symptoms.
Drug Interactions
Drug interactions may affect treatment effectiveness or toxicity. Inform the treating clinician of all prescriptions, over-the-counter products, herbal supplements and other treatments.
Pregnancy, Fertility and Breastfeeding
Some oncology and hematology medicines can cause fetal harm and require specific contraception or breastfeeding restrictions. Follow the medicine-specific official labeling and specialist advice.
Storage and Handling
Store according to the instructions printed on the actual Beacon Pharmaceuticals pack. Protect from inappropriate heat, humidity and light, and keep out of reach of children. Do not assume the storage conditions of another brand apply.
Why Is Certus Listed as an Alternative to Tykerb?
The comparison helps identify another listed brand containing Lapatinib. It does not establish identical formulation, regulatory approval, bioequivalence or permission to substitute.
Manufacturer Information
Listed brand: Certus. Manufacturer: Beacon Pharmaceuticals Ltd., Bangladesh. Reference brand: Tykerb. Generic: Lapatinib. Strength: 250 mg. Dosage form: Tablet.
Frequently Asked Questions
What is Certus 250 mg? It is a tablet containing Lapatinib 250 mg according to the supplied Beacon price list. What is it used for? Lapatinib is used in selected HER2-positive breast cancer combinations, subject to specialist assessment. Can it replace Tykerb? Not automatically; a qualified professional must check product-specific equivalence and regulatory requirements. Is a prescription required? Yes, appropriate prescription and specialist supervision are necessary.
Important Medical Disclaimer
This listing is for educational pharmaceutical identification only and is not a substitute for medical advice, official product labeling or regulatory review. Brand, strength and pack details should be confirmed against the current manufacturer information before dispensing.
| Generic Name | Lapatinib |
|---|---|
| Strength | 250 mg |
| Manufacturer | Beacon Pharmaceuticals Ltd. |
Related products
Femara 2.5 mg Alternative – Lexel (Letrozole) 2.5 mg Tablet | Beacon Pharmaceuticals
Ibrance 125 mg Alternative – Palbocent (Palbociclib) 125 mg Capsule | Incepta Pharmaceuticals
Palbocent 125 mg (Palbociclib) Capsule is listed in the supplied Lucent price catalogue attributed to Incepta Pharmaceuticals Ltd. Reference brand: Ibrance (Pfizer).
Pack: 21 capsules. Prescription medicine. Verify the exact manufacturer label and regulatory status; reference-brand comparison does not establish interchangeability.
Ibrance 125 mg Alternative – Palboxen (Palbociclib) 125 mg Capsule | Everest Pharmaceuticals
Palboxen 125 mg (Palbociclib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Ibrance (Pfizer). It belongs to the CDK4/6 inhibitor class and is used in selected HR-positive, HER2-negative breast cancer regimens.
Active ingredient: Palbociclib
Strength: 125 mg
Form: Capsule
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Ibrance 125 mg Alternative – Palker (Palbociclib) 125 mg Capsule | Beacon Pharmaceuticals
Kisqali 200 mg Alternative – Ribolib (Ribociclib) 200 mg Tablet | Beacon Pharmaceuticals
Kisqali 200 mg Alternative – Riboxen (Ribociclib) 200 mg Tablet | Everest Pharmaceuticals
Riboxen 200 mg (Ribociclib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Kisqali (Novartis). It belongs to the CDK4/6 inhibitor class and is used in selected HR-positive, HER2-negative breast cancer regimens.
Active ingredient: Ribociclib
Strength: 200 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Nolvadex 20 mg Alternative – Tamoxi (Tamoxifen) 20 mg Tablet | Beacon Pharmaceuticals
Piqray 150 mg Alternative – Alpesib (Alpelisib) 150 mg Tablet | Everest Pharmaceuticals
Alpesib 150 mg (Alpelisib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Piqray (Novartis). It belongs to the PI3K-alpha inhibitor class and is used in selected PIK3CA-mutated HR-positive, HER2-negative advanced breast cancer regimens.
Active ingredient: Alpelisib
Strength: 150 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.

Reviews
There are no reviews yet.